Top

Published in:

01-05-2020 | Overactive Bladder | Editorial

Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?

Authors: Ahmed El-Zawahry, Diaa E. E. Rizk

Published in: International Urogynecology Journal | Issue 5/2020

Excerpt

Overactive bladder syndrome (OAB) is a chronic urological condition that affects almost 20% of the population with a significant adverse impact on the quality of life. OAB may also have serious health consequences including mortality secondary to the increased risk of depression, falls and fractures. Thus far, the use of antimuscarinic therapy in OAB patients has been disappointing with reported compliance rates between 17%–35% after 2 years. Critical appraisal of novel pharmacological modalities for treatment of OAB, therefore, remains a research priority. …

Monteiro S, Riccetto C, Araujo A, Galo L, Brito N, Botelho S. Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. Int Urogynecol J. 2018;29(11):1565–73. https://doi.org/10.1007/s00192-018-3602-x.CrossRefPubMed

Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose? Int Urogynecol J. 2019;30(2):239–44. https://doi.org/10.1007/s00192-018-3640-4.CrossRefPubMed

Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder. Low Urin Tract Symptoms. 2017;9(1):27–32. https://doi.org/10.1111/luts.12103.CrossRefPubMed

Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-04022-8.

Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. https://doi.org/10.1016/j.eururo.2018.03.020.CrossRefPubMed

Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018;29(2):273–83. https://doi.org/10.1007/s00192-017-3377-5.CrossRefPubMed

Elmer-Lyon CG, Streit JA, Takacs EB, Ten Eyck PP, Bradley CS. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-04007-7.

Iyer S, Laus K, Rugino A, Botros C, Lozo S, Botros SM, et al. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2019;30(8):1253–9. https://doi.org/10.1007/s00192-018-3822-0.CrossRefPubMed

FDA Approves Mirabegron, Solifenacin Combo for OAB. http://fdadaily.com/2018/05/09/fda-approves-mirabegron-solifenacin-combo-for-oab/. 2018. Accessed 7/15/2019.

10.

Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35(5):827–38. https://doi.org/10.1007/s00345-016-1908-1.CrossRefPubMed

11.

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–45. https://doi.org/10.1016/j.eururo.2016.02.030.CrossRefPubMed

12.

Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75. https://doi.org/10.1111/bju.13882.CrossRefPubMed

Title: Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?
Authors: Ahmed El-Zawahry
Diaa E. E. Rizk
Publication date: 01-05-2020
Publisher: Springer International Publishing
Keywords: Overactive Bladder
Nerve Stimulation
Published in: International Urogynecology Journal / Issue 5/2020
Print ISSN: 0937-3462
Electronic ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-019-04121-6

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?

Excerpt

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2020

Commentary on “Effect of an exercise programme for reducing abdominal fat on overactive bladder symptoms in young overweight women”

Pelvic floor muscle training for female stress urinary incontinence: a randomised control trial comparing home and outpatient training

A commentary on “8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder”

Adherence and effectiveness of a single instruction of pelvic floor exercises: a randomized clinical trial

Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation

Better together: multidisciplinary approach improves adherence to pelvic floor physical therapy